Kunming Longjin Pharmaceutical

What Kunming Longjin Pharmaceutical does

Kunming Longjin Pharmaceutical Co., Ltd. (昆明龙津药业股份有限公司) is a Chinese vertically-integrated pharmaceutical company founded in 1991 and listed on the Shenzhen Stock Exchange (stock code 002750) since March 2015. The company is headquartered in Kunming, Yunnan Province, and operates a full industry chain spanning GAP-standard Erigeron breviscapus cultivation (2,000+ mu base), ethanol extraction (6 tons/year capacity), and freeze-dried powder injection production at a smart factory capable of 50 million vials annually. Its flagship product, Injection of Breviscapine (龙津®注射用灯盏花素), is the only Chinese Pharmacopoeia-standardized ≥98% purity monomer formulation and holds approximately 60% market share in its category, distributed across 1,400+ hospitals in 30+ provinces. The company has 38 granted invention patents, 11,000+ research publications, and 32,000 completed real-world clinical studies backing its therapeutic claims in cardiovascular and cerebrovascular disease.

The company generates revenue primarily through prescription drug sales via hospital bidding channels, with a secondary stream from raw material and Breviscapine extract sales to downstream pharmaceutical manufacturers, and emerging CMO/CDMO service preparation. Beyond the core cardiovascular franchise, the company has expanded into metabolic disorders, men's health (sildenafil and dapoxetine launches via subsidiary Yunnan Longjin Kangyou in 2024-2025), and generic drugs through partnerships with India's Intelliscend. R&D operations are split between Kunming (provincial-level technology center) and Suzhou. The company employs 230+ people with a 30-person R&D team and is controlled by Kunming Qunxing Investment Co., Ltd., founded by chairman Fan Xian'e, with his daughter Fan Lijuan serving as general manager. Products have obtained U.S. FDA self-GRAS certification for dietary supplement use and the company holds one granted U.S. patent, indicating nascent international ambitions.

Name

Kunming Longjin Pharmaceutical

Legal name

昆明龙津药业股份有限公司

Website

https://longjin.com.cn

Company type

Public

Founded year

1991

Operating status

Operating

Headcount range

101–250 employees

Short description

Kunming Longjin Pharmaceutical is a Yunnan-based, vertically-integrated Chinese pharmaceutical company specializing in Breviscapine cardiovascular injections (60% market share), now expanding into men's health and generic drugs through subsidiaries and international partnerships.

Ownership category

akta.pro rank

Product category

Pharmaceuticals (Cardiovascular and Cerebrovascular Drugs)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industry

Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB)

Keywords

• Chinese patent medicine
• Cardiovascular injectables
• Freeze-dried powder injections
• Botanical drug extraction
• Pharmaceutical manufacturing

Headquarters

HQ city

Kunming

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

1. 处方药（心脑血管及代谢类药物）销售: 公司核心收入来源，通过医院招标、政府采购、学术推广等处方药渠道销售，覆盖全国30+省份。核心产品注射用灯盏花素2018年按中标价计算平均销售近8亿元。主要产品包括：注射用灯盏花素、降纤酶、注射用生长抑素等15个品种规格。
2. 天然植物提取物（灯盏花素原料药）销售: 子公司南涧龙津生产灯盏花素原料药，产能6吨/年，采用乙醇提取工艺生产多种天然植物提取物，向客户提供定制化种植及提取服务。
3. CMO/代工生产服务: 基于成熟的智能制造、质量管理体系和对控股子公司受托生产经验，公司为承接外部CMO业务积极准备。
4. 大健康产品（灯盏花素延伸产品）: 灯盏花提取物可用于皮肤美白祛斑，对皮肤无副作用，可用于膳食补充剂（已获美国FDA self-GRAS认证），作为药品原料使用。

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Core offering

Kunming Longjin Pharmaceutical manufactures and sells prescription pharmaceutical products, primarily cardiovascular and cerebrovascular drugs led by Breviscapine for Injection (注射用灯盏花素), a freeze-dried powder injection. The company operates a fully integrated industry chain from GAP cultivation of Erigeron breviscapus (灯盏花素) through high-purity extraction of breviscapine API to finished freeze-dried powder formulation production. It also produces natural plant extracts, generic chemical drugs (via subsidiary Yunnan Longjin Kangyou), and offers CMO/contract manufacturing services. Sales reach 30+ Chinese provinces through hospital bidding, government procurement, and regional distributors.

Differentiator

Problem solved

Functional benefit

Products and services

• Breviscapine for Injection (注射用灯盏花素) / Longjin® brand Longjin's flagship freeze-dried powder injection (98%+ breviscapine purity) for treating cardiovascular and cerebrovascular diseases including stroke (acute and sequelae), coronary heart disease, and angina. Distributed through hospital channels covering 30+ provinces and 1,400+ hospitals. The product has approximately 60% market share in the breviscapine injection category.
• Bivalirudin for Injection (注射用比伐芦定) / Longjin® brand Anticoagulant freeze-dried powder injection for cardiovascular use, indicated for percutaneous coronary intervention (PCI) procedures. Launched by Longjin in 2023 and deemed equivalent to passing consistency evaluation.
• Breviscapine API / Natural Plant Extract (灯盏花素原料药/天然植提) High-purity breviscapine API (98%+) and other natural plant extracts produced at subsidiary Nanjian Longjin Bio-tech with 6 tons/year capacity. Sold to downstream pharmaceutical manufacturers and also used for food supplements (US FDA self-GRAS certified), skincare/whitening applications, and as raw material for drug production.
• Erigeron breviscapus GAP Cultivation Base (灯盏花GAP种植基地) 2000+ mu GAP-standard Erigeron breviscapus cultivation base operated by subsidiary Xuanwei Longjin Bio-tech. Supplies raw materials for company production and also sells to other pharmaceutical enterprises. The "Company + Project + Base + Cooperative + Farmer" model has driven 30,000+ mu of TCM materials cultivation in Xuanwei, benefiting 6,410 farmers.
• Dapoxetine Hydrochloride Tablets (盐酸达泊西汀片) Generic chemical drug for premature ejaculation treatment, launched by subsidiary Yunnan Longjin Kangyou Biopharmaceutical in 2025 for the men's health pharmaceutical market.
• Sildenafil Citrate Oral Disintegrating Tablets (枸橼酸西地那非口崩片) / Geli Duo® brand Generic erectile dysfunction medication in oral disintegrating tablet form, launched by subsidiary Yunnan Longjin Kangyou. Brand name Geli Duo (戈力多).
• Febuxostat Tablets (非布司他片) / Longjin Fengyao® brand Generic drug for gout and hyperuricemia treatment, brand Longjin Fengyao (津风瑶). Market authorization holder transferred to Longjin in 2025.
• Qiwei Tangnaishu Capsule (七味糖脉舒胶囊) Chinese patent medicine capsule for diabetes support and metabolic syndrome management. Market authorization transferred to Longjin in 2023.
• Ticagrelor Dispersible Tablets (替格瑞洛分散片) / Longjin Linli® brand Antiplatelet dispersible tablet for cardiovascular use, brand Longjin Linli (津琳莉). Listed for collaboration/intent partnership.
• Ezetimibe Tablets (依折麦布片) / Longjin Zhile® brand Cholesterol-lowering generic drug tablet, brand Longjin Zhile (津旨乐). Listed for collaboration/intent partnership.
• Febuxostat Tablets (non-transferred brand) / Longjin Fengyao brand Generic drug for gout treatment, listed for collaboration/intent partnership.
• Olmesartan Medoxomil Amlodipine Tablets (奥美沙坦酯氨氯地平片) / Shu'erle® brand Combination antihypertensive tablet for hypertension treatment, brand Shu'erle (舒尔乐). Listed for collaboration/intent partnership.
• CMO / Contract Manufacturing Services (CMO/代工生产服务) Contract manufacturing services leveraging the company's smart factory with 96%+ automation, integrated SCADA/MES/QMS systems, and 5,000 万 bottles/year production capacity. Preparations are underway to accept external CMO business from pharmaceutical companies.
• Defibrase for Injection (注射用降纤酶) Defibrase enzyme injection for cardiovascular and cerebrovascular disease treatment, part of the company's 15 product specifications catalog.

Quantifiable outcome

• 注射用灯盏花素市场份额约60%（南方所数据）
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

21 partnerships are on record, tiered 核心, 重要 and 一般.

• 印度Intelliscend药品研发公司核心Technology or Integration · 18 July 20192019年7月，龙津康佑与印度Intelliscend药品研发公司签订仿制药研发合作协议，引进印度先进技术进行高端仿制药研发，标志着龙津药业国际化迈出了关键一步。
• 印度CBC公司重要Channel Partner/ Reseller/ Distributor · 18 July 20192019年7月签约，CBC印度公司依托其在印度和中国的业务资源，为合作项目寻找原料药供应商，协助龙津康佑进行国际化布局。
• 宣威市龙津生物科技有限责任公司核心Others · 1 January 2017公司在宣威市投资2000多万元成立，从事灯盏细辛育种、种植、烘干技术培育，建有2000多亩GAP种植基地，带动当地中药材产业发展。
• 大理州灯盏花产业链企业（2家）重要Others · 1 January 20172017年公司投资4500万元并购位于云南省大理州的两家灯盏花产业链企业，2019年7月完成股权交割，年产6吨灯盏花素提取产能。
• 中国科学院昆明动物研究所核心Strategic or Co-development Partner2017年共同成立云南中科龙津生物科技有限公司，作为多肽类创新药物研发平台，合作开发利用天然活性多肽药物，开展多肽类创新药物研究，孵化有苗头的多肽药物项目。
• 中国科学院昆明植物研究所核心Strategic or Co-development Partner开展灯盏花素的质量标准体系研究，全面制定灯盏细辛育种、种植、药材，以及灯盏花素提取、饮品加工、生产技术、质量体系等的全产业链标准。
• 中国医学科学院药用植物研究所核心Strategic or Co-development Partner开展从新品系研发、良种选育、种子种苗繁育、标准化种植到成品质量控制提升的深度研究。
• 中国中医科学院中药研究所核心Strategic or Co-development Partner开展灯盏花素质量标准体系建设，进行灯盏花素提取、制剂加工、成品质量控制提升的深度研究。
• 云南农业大学核心Strategic or Co-development Partner开展灯盏花基因组测序、基因育种、分子标记、太空育种等现代育种技术合作，选育灯盏花新品系。
• 中国医学科学院北京药物研究所重要Strategic or Co-development Partner与公司联合开展注射用灯盏花素临床前有效性和安全性再研究，进行药理学和作用机制研究。
• 北京中医药大学重要Strategic or Co-development Partner合作开展基于网络药理学的注射用灯盏花素治疗心脑血管病作用机制研究，发表专家共识。
• 复旦大学药学院重要Strategic or Co-development Partner与公司在药物研发领域开展合作，进行在职人员深造培养。
• 浙江大学重要Strategic or Co-development Partner与公司建立广泛而紧密的合作关系，开展药物研发合作。
• 美国东卡罗来纳大学重要Strategic or Co-development Partner东卡罗来纳大学研究证实龙津®注射用灯盏花素对血管内皮细胞具有很好的修复和保护作用。
• 哈佛大学医学院重要Strategic or Co-development Partner与哈佛大学医学院保持长期友好合作关系。
• 江苏龙津康佑生物医药有限责任公司核心Others2019年成立，引入印度先进的仿制药技术，高效率开发心脑血管和代谢性疾病的仿制药，是公司高端仿制药开发平台。
• 云镶（上海）网络科技有限公司一般Technology or Integration合作进行智能穿戴等产品的研发生产，该公司生产的医疗级手环已可做血压监测和健康管理，是目前唯一心电图做到EGP准确度的手环。
• 德国/意大利设备供应商（联合上海东富龙）重要Technology or Integration联合上海东富龙公司设计建成冻干制剂生产线，主要设备由德国、意大利进口。
• 国家上海新药安全性评价中心核心Strategic or Co-development Partner委托完成龙津®注射用灯盏花素临床前系统安全性评价，揭示该产品最大安全剂量，证明有较宽的安全窗。
• 中国科学院上海药物所核心Strategic or Co-development Partner委托完成龙津®注射用灯盏花素非临床药代动力学研究，完整揭示药效物质基础在体内的药代特征、组织分布和药物对血脑屏障的通透性。
• 世界中医药学会联合会中药上市后再评价专业委员会重要Strategic or Co-development Partner委托开展32000例龙津®注射用灯盏花素真实世界的有效性和安全性研究。

Scale indicators19 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• China Resources Sanjiu Medical & Pharmaceutical (华润三九): Major Chinese OTC and prescription pharmaceutical company under China Resources with TCM and chemical drug portfolios; comparable to Longjin as a broad Chinese TCM pharmaceutical peer, though much larger in scale and brand presence.

Emerging players

• Zhejiang Huahai Pharmaceutical (华海药业): Chinese API and generic drug manufacturer with international (US FDA-approved) operations; comparable to Longjin's Longjin Kangyou subsidiary as a generic-drug expansion peer targeting regulated markets, though much larger in scale and overseas presence.

Regional players

• Yunnan Baiyao Group (云南白药集团): Major Yunnan-based Chinese TCM and consumer healthcare conglomerate; comparable to Longjin as a regional peer leveraging Yunnan botanical resources and TCM heritage, though considerably larger and more diversified into consumer products.

Direct peers

• Yiling Pharmaceutical (以岭药业): Shenzhen-listed TCM innovator with leading cardiovascular products such as Tongxinluo Capsule; closely comparable to Longjin in TCM-based cardiovascular therapy, hospital-channel prescription model, and integrated cultivation-to-extract-to-formulation value chain.
• Sichuan Kelun Pharmaceutical (科伦药业): Leading Chinese sterile injectable and infusion solution manufacturer with broad hospital channel coverage; comparable to Longjin in aseptic fill-finish manufacturing expertise, freeze-dried powder injection capability, and large hospital-distribution footprint.
• Shineway Pharmaceutical (石药集团/中国制药): Note: using CSPC Pharmaceutical as broader incumbent peer. Large Hong Kong-listed Chinese pharmaceutical manufacturer with strong injectable and cardiovascular franchises; comparable to Longjin in injectable formulation capabilities, cardiovascular product mix, and GMP-certified manufacturing scale.
• KPC Pharmaceuticals (昆药集团): Yunnan-based Chinese pharmaceutical manufacturer specializing in TCM formulations including cardiovascular indications; directly comparable to Longjin given shared Yunnan regional footprint, TCM injectable portfolio (e.g., Yiqi Yangyin injections), and similar hospital-channel business model.
• Livzon Pharmaceutical Group (丽珠医药): Shenzhen/HK-listed Chinese pharmaceutical company with established TCM injectables (e.g., Shenqiong injection), cardiovascular portfolio, and growing generic-drug business; comparable to Longjin across TCM injectables, cardiovascular indication mix, and pipeline diversification.
• China TCM Holdings (中国中药控股): Hong Kong-listed Chinese TCM pharmaceutical manufacturer with a broad portfolio of finished TCM products (injections, granules, capsules) sold via hospital channels; directly comparable to Longjin in TCM injectable manufacturing, hospital sales model, and regulatory-driven value proposition.
• Tianjin Tasly Pharmaceutical Group (天士力医药集团): Leading Chinese TCM pharmaceutical company focused on cardiovascular and cerebrovascular indications (e.g., compound Danshen preparations, Fufang Chuanxiong capsules); comparable to Longjin in TCM cardiovascular therapeutic focus, hospital-channel distribution, and standards-driven product strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/kunming-longjin-pharmaceutical-co-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kunming Longjin Pharmaceutical